• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by CHF Solutions, Inc.

    3/17/21 4:44:21 PM ET
    $CHFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CHFS alert in real time by email
    8-K 1 nt10021708x2_8k.htm FORM 8-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    FORM 8-K

    Current Report Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  March 17, 2021

    CHF Solutions, Inc.
    (Exact Name of Registrant as Specified in its Charter)

    Delaware
    001-35312
    No. 68-0533453
    (State or Other Jurisdiction of
    Incorporation or Organization)
    (Commission File Number)
    (I.R.S. Employer
    Identification No.)

    12988 Valley View Road, Eden Prairie, MN 55344
    (Address of Principal Executive Offices) (Zip Code)

    (952) 345-4200
    (Registrant’s Telephone Number, Including Area Code)

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
    CHFS
    Nasdaq Capital Market

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 1.01
    Entry into a Material Definitive Agreement

    Underwriting Agreement

    On March 17, 2021, CHF Solutions, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as representative (the “Representative”) of the underwriters identified therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 3,300,710 shares of its common stock, $0.0001 par value per share, at a public offering price of $5.50 per share (the “Offering”). Under the terms of the Underwriting Agreement, the Company granted the Underwriters a 45-day option to purchase up to an additional 495,106 shares of the Company’s common stock. The Company expects to receive approximately $16.5 million in net proceeds from the Offering (assuming the option to purchase additional shares is not exercised), after underwriting discounts and commissions and estimated Offering expenses payable by the Company. The Offering is scheduled to close on or about March 19, 2021, subject to customary closing conditions. The Company intends to use the net proceeds of the Offering for general corporate purposes, including the continued investment in commercialization efforts.

    The Underwriting Agreement contains representations, warranties and covenants made by the Company that are customary for transactions of this type. Under the terms of the Underwriting Agreement, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. In addition, pursuant to the terms of the Underwriting Agreement, the Company and its executive officers and directors have entered into agreements providing that the Company and each of these persons may not, without the prior written approval of the Representative, subject to limited exceptions, offer, sell, transfer or otherwise dispose of the Company’s securities for a period of 90 days following the Offering.

    The Offering was made pursuant to (i) the Company’s Registration Statement on Form S-3 (Registration No. 333-224881), filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2018 and declared effective by the SEC on May 23, 2018, (ii) the Company’s Registration Statement on Form S-3MEF (Registration No. 333-254373) and (iii) the related prospectus supplement filed with the SEC pursuant to Rule 424(b) dated March 17, 2021.

    The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

    Item 8.01
    Other Events

    On March 17, 2021, the Company issued a press release announcing the Offering (the “Press Release”). A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company is filing the opinion of its counsel, Honigman LLP, as Exhibit 5.1 hereto, regarding the legality of the shares issued pursuant to the Offering.

    Item 9.01
    Financial Statements and Exhibits

    (d)
    Exhibits

    Exhibit
    No.
     
    Description
         
    1.1
     
    Underwriting Agreement, dated March 17, 2021, between CHF Solutions, Inc. and Ladenburg Thalmann & Co. Inc., as the Representative of the several underwriters named in Schedule I thereto.
         
    5.1
     
    Opinion of Honigman LLP
         
    23.1
     
    Consent of Honigman LLP (included in Exhibit 5.1)
         
    99.1
     
    Press Release of CHF Solutions, Inc., dated March 17, 2021.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: March 17, 2021
    CHF SOLUTIONS, INC.
         
     
    By:
    /s/ Claudia Drayton
     
    Name: 
    Claudia Drayton
     
    Title:
    Chief Financial Officer


    Get the next $CHFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHFS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant

      EDEN PRAIRIE, Minn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Critically-ill children and babies with kidney failure or who are dependent on artificial kidney support currently do not have enough therapeutic options. Nuwellis (NASDAQ:NUWE) plans to fill this unmet need with the development of a fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. Nuwellis is a medical device company dedicated to transforming care for patients suffering from fluid imbalance. The new device will build on the existing technology of the company's Aquadex SmartFlow® system, and will be funded in part by a $1.7 million grant from the Nati

      8/5/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration

      EDEN PRAIRIE, Minn., July 13, 2021 (GLOBE NEWSWIRE) -- In an effort to increase the availability of life-saving ultrafiltration therapy to people experiencing fluid overload, the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code, 0692T for Therapeutic Ultrafiltration. The new CPT code will come into effect on January 1, 2022, at which time providers can utilize the code when using Aquadex® to deliver ultrafiltration to adults and children (20 kg or more). Aquadex is developed and marketed by Nuwellis, Inc. (NASDAQ:NUWE). A specific code for ultrafiltration was granted after a thorough review and validation that the technology met t

      7/13/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    SEC Filings

    See more
    • CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      4/27/21 8:15:21 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by CHF Solutions, Inc.

      DEF 14A - CHF Solutions, Inc. (0001506492) (Filer)

      4/13/21 4:43:22 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions, Inc. filed SEC Form 8-K: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers

      8-K - CHF Solutions, Inc. (0001506492) (Filer)

      4/5/21 5:16:56 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/24/21 11:03:40 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/23/21 8:52:19 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - CHF Solutions, Inc. (0001506492) (Subject)

      2/16/21 9:55:44 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by Wotta Paul

      3 - CHF Solutions, Inc. (0001506492) (Issuer)

      4/16/21 11:12:05 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by L John Erb

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:23:33 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by P. Thomas Lynch

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:22:39 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces New Appointments to Leadership Team

      EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex

      6/22/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions Appoints Nestor Jaramillo, Jr. as President and Chief Executive Officer

      EDEN PRAIRIE, Minn., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the appointment of President and Chief Operating Officer Nestor Jaramillo, Jr. to President and Chief Executive Officer (CEO), effective immediately. Predecessor CEO John Erb will continue to serve as the company’s Chairman of the Board. Mr. Jaramillo joined CHF Solutions in May 2019 and has driven the evolution of the company’s therapeutic focus strategy from solely heart failure to an expansion into critical care and pediatrics. His vision to transform the trajectory of cardiorenal disea

      1/19/21 8:00:00 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care